Cholestatic liver diseases (CLDs) are a group of disorders characterized by the impairment of bile formation, secretion, or ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has ...

Obeticholic acid was given accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not benefiting ... Given that obeticholic acid decreases bile acid synthesis, ...

Bile acids activate farnesoid X receptor (FXR) to repress the expression of CDO1 and CSAD to inhibit taurine synthesis and at the same time repress cholesterol 7⍺-hydroxylase (CYP7A1) to inhibit ...

The FDA approved Cholbam® (cholic acid) capsules) in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects ...

About Cholbam ® (cholic acid) The FDA approved Cholbam ® (cholic acid) capsules in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis ...

Medications that target bile acid-triggered pathways and combination therapies could be the key for treating nonalcoholic steatohepatitis for young people with obesity and type 2 diabetes ...

These bile acids, which are derived from the CYP7B1-centered alternative bile acid synthesis pathway, exhibit high efficacy in regulating glucose metabolism and predicting type 2 diabetes.

Mirum will purchase Travere's bile acid product portfolio for up to $445 million, consisting of $210 million upfront and $235 million in potential sales-based milestone payments.

Moreover, age-related reductions in bile acid synthesis reduces the utilization of cholesterol. These changes are collectively associated with excessive accumulation of cholesterol in the body.

The GLP-1 receptor agonist also increased reabsorption of bile acids more effectively than colesevelam ... [SeHCAT]), and also decreased bile acid synthesis (assessed by circulating C4).